scholarly journals Safety and Persistence of Infused CD19-Car-Modified Multivirus Specific CTLs in B Cell Malignancies Post Allogeneic Hematopoietic Stem Cell Transplantation

2012 ◽  
Vol 18 (2) ◽  
pp. S274
Author(s):  
C.R.Y. Cruz ◽  
K.P. Micklethwaite ◽  
B. Savoldo ◽  
S. Ku ◽  
R.A. Krance ◽  
...  
2015 ◽  
Vol 95 (6) ◽  
pp. 514-523 ◽  
Author(s):  
Petra Roll ◽  
Khalid Muhammad ◽  
Gernot Stuhler ◽  
Ulrich Grigoleit ◽  
Hermann Einsele ◽  
...  

2020 ◽  
Vol 19 (2) ◽  
pp. 22-30
Author(s):  
S. V. Chulkova ◽  
N. N. Subbotina ◽  
G. D. Petrova ◽  
N. V. Sidorova ◽  
O. P. Kolbatskaya ◽  
...  

The restoration of B-cell immunity is a key component of the success of allogeneic hematopoietic stem cell transplantation. In most cases, the restoration of B-lymphopoiesis is a slow and often incomplete process, which is accompanied by a decrease in the tolerance of the recipient to bacterial, viral, fungal pathogens. This process is influenced by a number of factors that determine its effectiveness and pace. It is important to restore not only the size of the B-cell population, but also their functional usefulness. The article provides an analysis of modern literature data on the significance of the restoration of B-cell immunity after allogeneic hematopoietic stem cell transplantation, a review of the main factors affecting the process of B-lymphopoiesis, and their prognostic component.


Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 7-7
Author(s):  
Chen Tian

High-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell transplantation (ASCT) is still a consolidation treatment choice for relapsed/refractory (R/R) B-cell Non-Hodgkin's lymphoma (NHL) patients and some aggressive B-cell NHL as frontline therapy. Due to the shortage of carmustine, we switched to idarubicin-substituted BEAC (IEAC). We compared the outcomes of 72 B-cell NHL patients treated with IEAC or BEAC regimens followed by ASCT. The median time to neutrophil and platelet reconstitution showed no difference between IEAC and BEAC groups. IEAC regimen was well tolerated without increase of adverse events. Transplant-related mortality didn't occur. The overall survival (OS) and progression-free survival (PFS) of IEAC group were a little longer than that of BEAC group. 2-year OS and PFS rate were higher in IEAC group compared to BEAC group. Multivariate analysis showed that AnnArbor staging, IPI score, lactate dehydrogenase (LDH) level, remission of disease, modified regimen were related with the prognosis. In conclusion, IEAC regimen was well tolerated and replacement with idarubicin could effectively prolong the survival of patients. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document